Epstein-Barr Virus Reactivation after Infliximab in Rheumatoid Arthritis: A Case Report-Reference-Cited by-同舟云学术

Epstein-Barr Virus Reactivation after Infliximab in Rheumatoid Arthritis: A Case Report

Published:2011 Issue: Volume:2011 Page:1-3
ISSN:2090-6625
Container-title:Case Reports in Infectious Diseases
language:en
Short-container-title:Case Reports in Infectious Diseases

Author:

Colaci Michele¹,Sebastiani Marco¹,Sandri Gilda¹,Meacci Marisa²,Ferri Clodoveo¹

Affiliation:

1. Rheumatology Unit, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41100 Modena, Italy

2. Microbiology and Virology Service, Policlinico di Modena, Via del Pozzo 71, 41100 Modena, Italy

Abstract

TNF-alpha blockers represent one of the most important therapeutic strategies for rheumatoid arthritis, but their use has raised the question about their safety profile, particularly in respect to viral infections/reactivations. We describe the case of a patient who developed a symptomatic EBV reactivation 11 days after the first infusion of infliximab.

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://downloads.hindawi.com/journals/criid/2011/530568.pdf

Reference11 articles.

1. Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis

2. Infections Associated With Tumor Necrosis Factor-α Antagonists

3. Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis

4. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epstein-Barr Virus Reactivation Causing Cholestatic Hepatitis;Cureus;2022-04-28

2. Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections;Expert Opinion on Drug Safety;2020-05-31

3. Reactivation of Epstein–Barr Virus Presenting as Massive Splenomegaly after Initiation of Golimumab Treatment;Case Reports in Hematology;2020-04-10

4. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents);Clinical Microbiology and Infection;2018-06

5. Hepatitis due to EBV-reactivation under infliximab in a psoriasis patient;Dermatologic Therapy;2017-08-02